BİROL OCAK, AHMET BİLGEHAN ŞAHİN, BAHAR DAKİKİ, HİKMET UTKU ODMAN, NESLİHAN HAZEL SAYDAM, SİBEL OYUCU ORHAN, TURGUT KAÇAN, ADEM DELİGÖNÜL, ERDEM ÇUBUKCU, TÜRKKAN EVRENSEL
Eurasian Journal of Medical Investigation - 2021;5(1):89-94
Objectives: Malignant pleural mesothelioma (MPM) accounts for approximately 80% of all mesothelioma cases. Methods: Forty-three patients diagnosed with advanced MPM were included in our study. We aimed to investigate first-line therapy options and the importance of platinum sensitivity in patients diagnosed with MPM, who were de novo metastatic or progressed from the early to the metastatic stage. Results: The mean age of the patients was 58.8±11.7 years, and 58.1% (25 patients) were male. The median overall survival (OS) was found to be 10.5 months (CI 95% 5.8-15.2). Median progression-free survival (PFS) of all MPM patients was 7.6 months (CI 95% 6.2-7.9). When comparing the platinum-sensitive group to the platinum-resistant group, the median OS of the platinum-sensitive group was found to be 10.5 months (CI 95% 4.6-16.5), and the median OS of the platinum-resistant group was 3.3 months (CI 95% 3.1-3.6) (p=0.02). The median PFS of the platinumsensitive group was 7.9 months (CI 95% 5.9-9.9), while that for the platinum-resistant group was 2.4 months (CI 95% 2.1-2.8) (p<0.01). Conclusion: Platinum-based chemotherapy regimens should be considered first at the metastatic stage.
